SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2024
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, County. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b): 82-
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279,
333-195232 and 333-253070) and Registration Statements on Form F-3 (File Nos. 333-267160, 333-279017 and 333-280391).
Trinity Biotech plc Announces Results of Annual General Meeting
At the Annual General Meeting (the “Meeting”) of the Company held on September 30, 2024, shareholders approved the following
resolutions (as more fully set out in the Notice of the Meeting dated September 5, 2024):
| 1. |
To re-appoint Grant Thornton as statutory auditor of the Company to hold office until the conclusion of the next Annual General Meeting at which accounts are laid
before the Company.
|
| 2. |
To authorise the board of directors to fix the statutory auditors' remuneration.
|
| 3. |
To re-appoint Dr Andrew Omidvar as a director who retires, and being eligible, offers himself for re-appointment.
|
After the Meeting, the Board of Directors resolved to appoint Thomas Lindsay as a director of the Company on an interim basis until the
next Annual General Meeting given, amongst other reasons, the obligation of the Company to maintain an independent audit committee, which is a role Mr. Lindsay fulfils.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
| |
TRINITY BIOTECH PLC
|
|
| |
|
Trinity Biotech plc
|
|
| |
|
(Registrant)
|
|
| |
|
|
|
| |
By:
|
/s/ Louise Tallon
|
|
| |
|
Louise Tallon
|
|
| |
|
Chief Financial Officer
|
|
Date: September 30, 2024